GLP-1/GIP receptor dual agonist
Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial
HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics